Medical University of South Carolina, Charleston, SC, USA.
School of Medicine, University of Florida, Gainesville, FL, USA.
Pediatr Cardiol. 2022 Aug;43(6):1251-1263. doi: 10.1007/s00246-022-02846-8. Epub 2022 Mar 3.
Barth Syndrome (BTHS) is an X-linked mitochondrial cardioskeletal myopathy caused by defects in TAFAZZIN, a gene responsible for cardiolipin remodeling. Altered mitochondrial levels of cardiolipin lead to cardiomyopathy (CM), muscle weakness, exercise intolerance, and mortality. Cardiac risk factors predicting outcome are unknown. Therefore, we conducted a longitudinal observational study to determine risk factors for outcome in BTHS. Subjects with minimum two evaluations (or one followed by death or transplant) were included. Cardiac size, function, and QTc data were measured by echocardiography and electrocardiography at 7 time points from 2002 to 2018. Analysis included baseline, continuous, and categorical variables. Categorical risk factors included prolonged QTc, abnormal right ventricle fractional area change (RV FAC), left ventricle (LV) or RV non-compaction, and restrictive CM phenotype. The association between variables and cardiac death or transplant (CD/TX) was assessed. Median enrollment age was 7 years (range 0.5-22; n = 44). Transplant-free survival (TFS) was 74.4% at 15 years from first evaluation. The cohort demonstrated longitudinal declines in LV size and stroke volume z-scores (end-diastolic volume, p = 0.0002; stroke volume p < 0.0001), worsening RV FAC (p = 0.0405), and global longitudinal strain (GLS) (p = 0.0001) with stable ejection (EF) and shortening (FS) fraction. CD/TX subjects (n = 9) displayed worsening LV dilation (p = 0.0066), EF (p ≤ 0.0001), FS (p = 0.0028), and RV FAC (p = .0032) versus stability in TFS. Having ≥ 2 categorical risk factors predicted CD/TX (p = 0.0073). Over 15 years, 25% of BTHS subjects progressed to CD/TX. Those with progressive LV enlargement, dysfunction, and multiple cardiac risk factors warrant increased surveillance and intense therapy.
巴特综合征(Barth Syndrome,BTHS)是一种 X 连锁的线粒体心脏骨骼肌病,由tafazzin 基因突变引起,tafazzin 基因负责调节心磷脂的重塑。心磷脂在线粒体中的水平改变会导致心肌病(cardiomyopathy,CM)、肌肉无力、运动不耐受和死亡率升高。目前尚不清楚预测结局的心脏危险因素。因此,我们进行了一项纵向观察性研究,以确定 BTHS 患者的结局危险因素。纳入了至少接受 2 次评估(或 1 次随访后死亡或移植)的患者。通过超声心动图和心电图在 2002 年至 2018 年期间的 7 个时间点测量心脏大小、功能和 QTc 数据。分析包括基线、连续和分类变量。分类危险因素包括 QTc 延长、右心室分数面积变化(RV FAC)异常、左心室(LV)或右心室非致密化以及限制型 CM 表型。评估了变量与心脏死亡或移植(cardiac death or transplant,CD/TX)之间的关系。中位入组年龄为 7 岁(范围 0.5-22 岁;n=44)。从首次评估开始,15 年后无移植生存率(transplant-free survival,TFS)为 74.4%。该队列表现出 LV 大小和每搏输出量 z 评分的纵向下降(舒张末期容积,p=0.0002;每搏输出量 p<0.0001),RV FAC 恶化(p=0.0405)和整体纵向应变(GLS)恶化(p=0.0001),射血分数(EF)和缩短分数(FS)稳定。CD/TX 患者(n=9)的 LV 扩张恶化(p=0.0066)、EF(p≤0.0001)、FS(p=0.0028)和 RV FAC(p=0.0032)恶化,而 TFS 稳定。存在≥2 个分类危险因素可预测 CD/TX(p=0.0073)。在 15 年期间,25%的 BTHS 患者进展为 CD/TX。那些 LV 扩大、功能障碍和存在多种心脏危险因素的患者需要加强监测和强化治疗。